BMS, Pfizer halt Apixaban Phase 3 APPRAISE-2 trial
BMS and Pfizer said that the study was stopped early based on the recommendation of an independent Data Monitoring Committee (DMC). There was clear evidence of a clinically
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.